Navidea Biopharma (NAVB) Announces Positive Results Encompassing Additional Patients From Its Ongoing Phase 2B Study in Rheumatoid Arthritis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. APGE
5. USO
6. MU
7. HOOD
8. DFTX
9. GOOGL
10. ABBV

Go back to Navidea Biopharma (NAVB) Announces Positive Results Encompassing Additional Patients From Its Ongoing Phase 2B Study in Rheumatoid Arthritis

Navidea Biopharma (NAVB) Misses Q3 EPS by 4c

November 12, 2020 4:04 PM EST

Navidea Biopharma (NYSE: NAVB) reported Q3 EPS of ($0.13), $0.04 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $268 thousand versus the consensus estimate of $150 thousand.

Third Quarter 2020 Highlights and Subsequent Events

Executed a binding memorandum of understanding (MOU) on August 9, 2020 with Jubilant Draximage Inc. dba Jubilant Radiopharma, Radiopharmaceuticals Division (Jubilant). The MOU outlines the terms and framework for an Exclusive License and Distribution Agreement for Navideas Rheumatoid Arthritis Diagnostic in the United States, Canada, Mexico, and Latin America. In connection with the MOU, Jubilant made a $1 million equity investment in... More